Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Waisman Biomanufacturing, part of the Waisman Center at the University of Wisconsin-Madison, is a premier contract development and manufacturing organization (CDMO). It specializes in producing high-quality biologics, including plasmid DNA, recombinant proteins, viral vectors, and cell-based therapeutics, under Current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials. Catering to academic researchers, biotech startups, and pharmaceutical companies, Waisman Biomanufacturing offers comprehensive services from process development and scale-up to analytical testing and regulatory support, effectively bridging the gap between preclinical research and clinical application of novel therapies.
Serves as the central hub for all cGMP manufacturing operations, process development, quality control, quality assurance, project management, and business development activities. It houses state-of-the-art cleanroom suites and laboratories.
Multiple cGMP-compliant cleanroom suites (Grade B/C/D) for viral vector production, cell therapy processing, microbial fermentation, and protein purification. Advanced analytical and quality control laboratories. Proximity to the extensive research resources and expertise of the University of Wisconsin-Madison.
Characterized by a blend of academic rigor and industry-standard cGMP practices. It fosters a highly collaborative, team-oriented environment where scientists, engineers, and quality professionals work closely on complex biomanufacturing projects. Emphasis is placed on meticulous attention to detail, continuous learning, and a shared mission of advancing human health through innovative therapies.
Plays a critical role in the biotechnology ecosystem by enabling the translation of cutting-edge scientific discoveries, particularly from academic and small biotech entities, into clinical-grade materials for human trials. It helps de-risk and accelerate the development of novel therapies.
While Waisman Biomanufacturing operates from its primary facility in Madison, Wisconsin, its impact and collaborations are global. The facility manufactures products for clients and research partners worldwide, supporting clinical trials conducted in various countries. Its expertise contributes to the international advancement of novel biopharmaceuticals, gene therapies, and cell therapies.
1500 Highland Ave
Madison
Wisconsin
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Waisman Biomanufacturing' leadership includes:
Waisman Biomanufacturing has been backed by several prominent investors over the years, including:
Based on publicly available information, Waisman Biomanufacturing's core leadership team has remained stable, with no major executive hires or departures publicly announced in the last 12 months. The continuity in leadership supports their ongoing strategic initiatives and operational excellence.
Discover the tools Waisman Biomanufacturing uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
As part of the University of Wisconsin-Madison and the Waisman Center, Waisman Biomanufacturing personnel typically use email addresses associated with the university's domain. Common formats include [last]@[waisman.]wisc.edu or [first_initial][last]@[waisman.]wisc.edu.
[last]@waisman.wisc.edu or [first_initial][last]@wisc.edu
Format
dattilo@waisman.wisc.edu
Example
80%
Success rate
Waisman Center News • November 9, 2023
Waisman Biomanufacturing announced the successful cGMP manufacturing of ABO-201 (scAAV9.PIGN), a novel gene therapy product developed by Abeona Therapeutics for CLN3 disease, a fatal pediatric neurodegenerative disorder. This achievement underscores Waisman's capability in producing complex viral vectors for clinical use....more
Waisman Center News • June 1, 2023
Waisman Biomanufacturing is collaborating with Opsis Therapeutics to produce cell-based therapies derived from human induced pluripotent stem cells (iPSCs) aimed at treating retinal degenerative diseases. This partnership highlights their role in advancing cutting-edge treatments for vision loss....more
Wisconsin State Journal • February 14, 2023
An article highlighting the role of Carl Ross, Managing Director of Waisman Biomanufacturing, and the facility's critical function in advancing cell and gene therapies from research stages to clinical application, emphasizing its unique position within UW-Madison....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Waisman Biomanufacturing, are just a search away.